Our aim is to describe the performance, accuracy and safety profile of 19G and 22G Procore needles (Cook Medical Inc, Limerick Ireland). Methods: We retrospectively reviewed patients referred to for EUS-FNB with 19G and 22G ProCore needles. Seventeen patients were identified with 24 lesions. EUS-FNB was performed with a convex array linear echoendoscope (Olympus, GF-UCT140-AL5, Japan) attached to Prosound α5/SSD-500 (Aloka Co. Ltd. Tokyo, Japan) ultrasound machine. Results were compared to surgical histopathology, or global clinical and radiological assessment and follow-up on non-operated cases. Results: EUS-FNBs were technically feasible in

21 (87.5%) cases. Clinical data of 21 lesions

from 17 patients (14 male, 3 females) were included for analysis. Mean age of patients Barasertib cost were 63.6 ± 10.6 years, (range 39.2–75.6). Both 19G and 22G ProCore needle were used in 9 (42.9%) and 12 (57.1%) lesions. Mean size of lesion was 29.2 ± 12.8 mm, (range 10.0–62.0 mm). Mean passes performed were 2.3 ± 1.2 (range 1–5) with median of 3 passes. Three cases from 22G needle did not yield adequate tissue. No statistical significance in the type of needle used for sampling adequacy (p = 0.229). The sensitivity, CAL-101 purchase specificity, positive predictive value and negative predictive value and accuracy for malignancy were 100.0%. No complication was noted. Conclusion: The performance of EUS-FNB with 19G and 22G ProCore needle is an accurate and safe procedure in our center.

Both needles were suitable for tissue procurement. Key Word(s): 1. Endoscopic; 2. Fine needle biopsy; 3. Ultrasound; 4. ProCore; Presenting Author: LIPING YAO Additional Authors: HONGBO ZHANG, ZHIGUO LIU, NA LIU, KAICHUN WU, DAIMING 上海皓元 FAN Corresponding Author: LIPING YAO Affiliations: State Key Laboratory of Cancer Biology & Xijing Hospital of Digestive Diseases, Fourth Military Medical University Objective: Achalasia is a chronic progressive benign disease with severe morbidity and difficult management. Peroral endoscopic myotomy (POEM) is a novel endoscopic operation for the treatment of achalasia. This study presents 6-month symptomatic and physiological outcomes after POEM for achalasia. Methods: Nineteen esophageal achalasia patients who underwent POEM in our institution between December 2011 and October 2012 were enrolled. Under general anesthesia, initial incision was made on the posterior wall of the esophagus after submucosal injection. Submucosal tunnel was created and extended below the lower esophageal sphincter (LES) onto the gastric cardia. Hemostatic clips were used to close the mucosal entry. Pre- and postoperative symptoms were quantified with Eckardt scores.